Navigation Links
Medarex Announces 2008 First Quarter Financial Results

PRINCETON, N.J., May 12 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: MEDX) announced today its financial results for the quarter ended March 31, 2008.

Including a gain of $151.8 million, or $1.19 per share, from Medarex's sale of 2.5 million shares of Genmab A/S stock in February 2008, Medarex's net income for the quarter ended March 31, 2008, was $103.3 million, or $0.81 per share, as compared to a net income of $110.3 million, or $0.88 per share for the same period in 2007. In addition to the gain on the sale of Genmab A/S stock, Medarex's net income for the quarter ended March 31, 2008 included a loss of $2.9 million, or ($0.02) per share, representing Medarex's share of the 2008 net loss of Celldex Therapeutics, Inc. (a subsidiary of Medarex) prior to its merger with AVANT Immunotherapeutics, Inc., and a non-cash charge of $5.3 million, or ($0.04) per share, for stock-based compensation recorded in accordance with FAS 123(R). Excluding the impact of these items, Medarex's net loss on a non-GAAP basis for the first quarter of 2008 was $38.5 million, or ($0.30) per share.

Total revenues for the quarter ended March 31, 2008, were $12.0 million as compared to $11.5 million in 2007.

Research and development (R&D) expenses for the quarter ended March 31, 2008, increased by $2.3 million, from $47.0 million in 2007 to $49.3 million in 2008. General and administrative expenses increased by $1.1 million for the quarter ended March 31, 2008, from $11.3 million in 2007 to $12.4 million in 2008.

Medarex ended the first quarter of 2008 with approximately $464.5 million in cash, cash equivalents and marketable securities. In addition, the fair market value of Medarex's equity interest in Genmab was approximately $115.6 million as of March 31, 2008.

Non-GAAP Financial Measurements

This press release and the accompanying tables include non-GAAP financial measures. Please see the section of the accompanying tables titled "Reconciliation of GAAP Net Income to Non-GAAP Net Loss" for a description of these non-GAAP financial measures, including reasons for Medarex management's decision to use each measure, and reconciliations of these non-GAAP financial measures to the most directly comparable financial measures prepared in accordance with Generally Accepted Accounting Principles.

Medarex's product development and business activities during the first quarter of 2008 include the following:

-- Announcing the receipt of a milestone payment from our licensing

partner, Centocor, Inc., in connection with Centocor's submission of a

regulatory application to the European Medicines Agency requesting

marketing approval of golimumab (CNTO 148), a human anti-TNF antibody

for the treatment of rheumatoid arthritis, psoriatic arthritis and

ankylosing spondylitis, that was generated using Medarex's UltiMAb(R)


-- Announcing the receipt of a milestone payment from our licensing

partner, Novo Nordisk A/S, for the filing of an Investigational New

Drug application for an antibody generated by Medarex's UltiMAb(R)

technology; and

-- Adding approximately $152 million to our cash resources through the

sale of Genmab A/S common stock, reducing our ownership in Genmab to

approximately 5.1% of the total outstanding shares.

"This is an exciting time for Medarex, and we begin the year with continued focus on laying the groundwork for sustained growth and value by investing in and making positive advances with products in our pipeline," said Howard H. Pien, President and CEO of Medarex.

As previously announced, 17 presentations for ipilimumab and antibodies targeting PD-1 and CD70 are expected at the upcoming annual meeting of the American Society of Clinical Oncology (ASCO) in May.

About Medarex

Medarex is a biopharmaceutical company focused on the discovery, development and potential commercialization of fully human antibody-based therapeutics to treat life-threatening and debilitating diseases, including cancer, inflammation, autoimmune disorders and infectious diseases. Medarex applies its UltiMAb(R) technology and product development and clinical manufacturing experience to generate, support and potentially commercialize a broad range of fully human antibody product candidates for itself and its partners. Over forty of these therapeutic product candidates derived from Medarex technology are in human clinical testing or have had INDs submitted for such trials, with seven of the most advanced product candidates currently in Phase 3 clinical trials or the subject of regulatory applications for marketing authorization. Medarex is committed to building value by developing a diverse pipeline of antibody products to address the world's unmet healthcare needs. For more information about Medarex, visit its website at

Statement on Cautionary Factors

Except for the historical information presented herein, the statements relating to Medarex's investments and advances related to its products in this press release may constitute forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995, that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Medarex disclaims, however, any intent or obligation to update these forward-looking statements. Risks and uncertainties include risks associated with product discovery and development, uncertainties related to the outcome of clinical trials, slower than expected rates of patient recruitment, unforeseen safety issues resulting from the administration of antibody products in patients, uncertainties related to product manufacturing, the need for additional capital, compliance with regulatory requirements, risks associated with the use of hazardous substances and risks associated with the enforceability of our patents as well as risks detailed from time to time in Medarex's public disclosure filings with the U.S. Securities and Exchange Commission (SEC), including its Annual Report on Form 10-K for the fiscal year ended December 31, 2007. There can be no assurance that such development efforts will succeed or that developed products will receive required regulatory clearance or that, even if such regulatory clearance were received, such products would ultimately achieve commercial success. Copies of Medarex's public disclosure filings are available from its investor relations department.

Medarex(R), the Medarex logo and UltiMAb(R) are registered trademarks of Medarex, Inc. All rights are reserved.


Condensed Consolidated Statements of Operations

(In thousands, except per share data)

Three Months Ended

March 31,


2008 2007

Contract and license revenues $7,984 $6,998

Reimbursement of development costs 4,019 4,541

Total revenues 12,003 11,539

Costs and expenses:

Research and development 49,292 47,022

General and administrative 12,409 11,302

Operating loss (49,698) (46,785)

Equity in net loss of affiliate (1,785) -

Investment and interest income, net 154,818 155,401

Minority interest - Celldex - 1,651

Income before provision for income taxes 103,335 110,267

Provision for income taxes 23 2

Net income $103,312 $110,265

Basic net income per share $0.81 $0.88

Diluted net income per share $0.76 $0.80

Weighted average number of common

shares outstanding during

the year - basic 127,643 124,690

- diluted 138,580 140,144

Condensed Consolidated Balance Sheets

(In thousands)

March 31, December 31,

2008 2007

(unaudited) (1)

Cash, cash equivalents and marketable

securities - Medarex $464,477 $486,772

Cash and cash equivalents - Celldex - 14,000

Other current assets 15,818 29,013

Property, buildings and equipment, net 75,966 79,925

Marketable securities - Genmab 115,587 139,165

Investments in Avant Immunotherapeutics 9,381 -

Investments in, and advances to affiliate

and partners 6,040 6,040

Segregated cash - non current 1,300 1,530

Other assets 2,206 3,415

$690,775 $759,860

Current liabilities $64,319 $81,645

Other liabilities 86,170 89,454

Convertible notes 143,986 143,505

Shareholders' equity 396,300 445,256

$690,775 $759,860

(1) Derived from the December 31, 2007 audited financial statements. For

further information, refer to the consolidated financial statements

and footnotes thereto included in Medarex's Annual Report on Form 10-K

for the year ended December 31, 2007.

This press release dated May 12, 2008, contains non-GAAP financial measures. The following table reconciles the non-GAAP financial measures contained in the press release to the most directly comparable financial measures prepared in accordance with GAAP. These non-GAAP financial measures include non-GAAP net loss and non-GAAP net loss per share. Non-GAAP financial measures should be considered in addition to, and not as a substitute for, or superior to, financial measures prepared in accordance with GAAP.

The following reconciliation of GAAP net income to non-GAAP net loss and GAAP net income per share to non-GAAP net loss per share is provided as a complement to results presented in accordance with GAAP because Medarex's management believes these non-GAAP financial measures provide better insight into Medarex's performance by focusing on results generated by its ongoing operations and are important in comparing current results with prior period results. Non-GAAP net loss and non-GAAP net loss per share are intended to illustrate Medarex's results of operations for the periods presented excluding the items discuss below. Medarex's management believes investors' understanding of Medarex's financial performance is enhanced as a result of our disclosing these non-GAAP financial measures. Non-GAAP net loss and non- GAAP net income per share should not be viewed in isolation or as a substitute for GAAP net loss or GAAP net income per share.


Reconciliation of GAAP Net Income to Non-GAAP Net Loss

(In thousands, except per share data)


Three Months Ended March 31,

2008 2007

GAAP net income $103,312 $110,265

Celldex net loss (1) 2,924 4,128

Minority interest - Celldex (1) - (1,651)

Stock-Based compensation expense (2) 5,291 3,498

Equity in net loss of affiliate 1,785 -

Gain on sale of Genmab stock (151,834) (152,143)

Non-GAAP Net loss $(38,522) $(35,903)

GAAP Net income (loss) per share,

basic $0.81 $0.88

diluted $0.76 $0.80

Non-GAAP Net loss

per share, basic and diluted $(0.30) $(0.29)

Shares used in computing basic and diluted

Non-GAAP net loss per share 127,643 124,690

(1) In management's view, the operations of Celldex prior to its merger

with AVANT Immunotherapeutics, Inc. (effective March 7, 2008) are not

necessarily indicative of, or directly attributable to, Medarex's

continuing operations. Celldex's operations relate primarily to the

research, development and commercialization of therapeutic vaccines,

which is outside the scope of Medarex's core business operations.

(2) For the three months ended March 31, 2008, Medarex incurred $5.3

million in non-cash stock compensation expense, of which $2.0 million

is included in research and development expenses and $3.3 million is

included in general and administrative expenses. Stock compensation

expense includes costs associated with stock awards, including stock

options which were recorded in accordance with the provisions of FAS

123(R). FAS 123(R) requires companies to record stock-based payments

in the financial statements using a fair value method. Medarex adopted

FAS 123(R) on a modified prospective basis beginning on January 1,


In addition to excluding the items described in footnotes 1 and 2 above, items have been excluded based upon management's evaluation (on an individual basis) of both quantitative and qualitative aspects of the item, including, (i) size and nature, (ii) whether it relates to our ongoing business operations, and (iii) whether management expects it to occur as part of our normal business on a regular basis. Those additional items excluded for purposes of determining non-GAAP net loss and non-GAAP net loss per share are gain on sales of Genmab stock and equity in net loss of affiliate.

SOURCE Medarex, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Medarex and Bristol-Myers Squibb Joint Statement on Submission Status of Ipilimumab
2. Medarex Announces 2007 Fourth Quarter and Year End Financial Results
3. Medarex to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
4. Medarex to Receive Milestone Payment for Submission of Regulatory Applications Requesting Approval of Ustekinumab (CNTO 1275) for Treatment of Psoriasis
5. PharmAthene and Medarex Announce Additional $0.8 Million U.S. Government Appropriation for Continued Development of Anthrax Therapeutic Valortim(TM)
6. Medarex to Present at the JPMorgan Small/Mid Cap Conference
7. Ono and Medarex Announce Allowance of Investigational New Drug Application for Fully Human Anti-PD1 Antibody
8. Medifast Announces First Quarter 2008 Financial Results
9. Esperanza Announces Support of H.R. 1108, Encourages Congress to Pass FDA Regulation of Tobacco
10. Pregis Announces First Quarter 2008 Financial Results
11. Almost Family, Inc. Announces Exercise of Over-Allotment Option
Post Your Comments:
(Date:12/1/2015)... Illinois (PRWEB) , ... December 01, 2015 , ... ... and share medical images have been lifted as IMAGE Information Systems launches MED-TAB™ ... Society of North America Annual Meeting from November 29 to December 4, 2015. ...
(Date:12/1/2015)... ... December 01, 2015 , ... For many X-rays taken at ... accurate interpretation by the radiologist. The marking utensils are so small, however, they ... found a way to alleviate this problem. , He developed the patent-pending MARK ...
(Date:12/1/2015)... CA (PRWEB) , ... December 01, 2015 , ... ... Health Center of Excellence (BHCOE) today announced that the organization has awarded Education ... San Francisco, with a Distinguished Award. The award celebrates exceptional special needs providers ...
(Date:12/1/2015)... ... ... Lutronic, a leading innovator of aesthetic and medical laser and energy-based technology, announced ... the United States. Clarity is a Superior Dual Wavelength Platform which combines two ... platform that is easy to own and operate. , For over a decade, ...
(Date:12/1/2015)... (PRWEB) , ... December 01, 2015 , ... XTC ... selected 10 semi-finalists to head to Las Vegas for CES 2016, the world’s largest ... CEO of Consumer Technology Association Gary Shapiro, Founding Partner of Pacific Investments Veronica Serra, ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... Dec. 1, 2015   Nottingham Spirk , ... announced the publication of a free whitepaper ... Medical Market". The whitepaper gives medical product companies, ... penetrating this lucrative segment. Nottingham Spirk ... to manage their own health, save money (i.e., ...
(Date:12/1/2015)... BOULDER, Colo. , Dec. 1, 2015 ... ARRY ) today announced that its Chief ... present at the Oppenheimer Annual Healthcare Conference ... to participate in the conference through a ... , --> ...
(Date:12/1/2015)... BANGALORE, India and ... (NASDAQ, TASE: MYL) today announced that it expects to ... for developing country markets funded by international donors, TLE400 ... + Efavirenz 400 mg) for $99 per patient, per ... (CHAI) to develop TLE400. The significantly reduced price could ...
Breaking Medicine Technology: